Cardiac calcineurin during transition from hypertrophy to heart failure in rats

Biochemical and Biophysical Research Communications

Volumn 273, Issue 1, 2000, Pages 347-351

  Hayashida, Wataru ^a   Kihara, Yasuki ^a   Yasaka, Asuka ^a   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE inhibitor; Calcineurin; Cyclosporin A; Dahl salt sensitive rats; Heart failure; Hypertrophy

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TEMOCAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLE; WEIGHT;

EID: 0034709643     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2893     Document Type: Article

References (26)

1. Batuik T. D., Halloran P. F. The downstream consequence of calcineurin inhibition. Transplant. Proc. 29:1997;1890-1892.
2. Su Q., Zhao M., Weber E., Eugster H. P., Ryffel B. Distribution and activity of calcineurin in rat tissues. Evidence for post-transcriptional regulation of tissue-specific calcineurin B. Eur. J. Biochem. 230:1995;469-474.
3. Molkentin J. D., Lu J.-R., Antos C. L., Markham B., Richardson J., Robbins J., Grant S. R., Olson E. N. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
4. Sussman M. A., Lim H. W., Gude N., Taigen T., Olson E. N., Robbins J., Colbert M. C., Gualberto A., Wieczorek D. F., Molkentin J. D. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.
5. Meguro T., Hong C., Asai K., Takagi G., McKinsey T. A., Olson E. N., Vatner S. F. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84:1999;735-740.
6. Luo Z., Shyu K.-G., Gualberto A., Walsh K. Calcineurin inhibitors and cardiac hyperrophy. Nature. Med. 4:1998;1092-1093.
7. Muller J. G., Nemoto S., Laser M., Carabello B. A., Menick D. R. Calcineurin inhibition and cardiac hypertrophy. Science. 282:1998;1007a.
8. Zhang W., Kowal R. C., Rusnak F., Sikkink R. A., Olson E. N., Victor R. G. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ. Res. 84:1999;722-728.
9. Ding B., Price R. L., Borg T. K., Weinberg E. O., Halloran P. F., Lorell B. H. Pressure overload induces severe hypertorphy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ. Res. 84:1999;729-734.
10. Lim H. W., Molkentin J. D. Calcineurin and human heart failure. Nature. Med. 5:1999;246-247.
11. Tsao L., Neville C., Musaro A., McCullagh K. J. A., Rosenthal N. Revisiting calcineurin and human heart failure. Nature Med. 6:2000;2-3.
12. Gomez A. M., Valdiva H. H., Cheng H., Lederer M. R., Santana L. F., Cannel M. B., McCune S. A., Atschuld R. A., Lederer W. J. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 276:1997;800-806.
13. Inoko M., Kihara Y., Morii I., Fujiwara H., Sasayama S. Transition from compensatory hypertrophy to dilated, failing ventricles in Dahl salt-sensitive rats. Am. J. Physiol. 267:1994;H2471-H2482.
14. Iwanaga Y., Kihara Y., Hasegawa K., Inagaki K., Yoneda T., Kaburagi S., Araki M., Sasayama S. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation. 98:1998;2065-2073.
15. Frunman D. A., Klee C. B., Brierer B. E., Burkoff S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin. Proc. Natl. Acad. Sci. USA. 89:1992;3686-3690.
16. Hayashida W., van Eyll C., Rousseau M. F., Pouleur H. Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: Modification by long-term enalapril treatment. J. Am. Coll. Cardiol. 22:1993;1403-1410.
17. Weinberg E. O., Schoen F. J., George D., Kagaya Y., Benedict C. R., Lorell B. H. Angiotensin converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 90:1994;1410-1422.
18. 2 receptors, regulates STAT activation by negative crosstalk. Circ. Res. 84:1999;876-882.
19. Mende U., Kagen A., Cohen A., Aramburu J., Schoen F. J., Neer E. J. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl. Acad. Sci. USA. 95:1998;13893-13898.
20. Rao A., Luo C., Hogan P. G. Transcriptional factors of the NFAT family: Regulation and function. Annu. Rev. Immunol. 15:1997;707-747.
21. Hoey T., Sn Y. L., Williamson K., Xu X. Isolation of two new members of the NFAT gene family and functional characterization of the NFAT proteins. Immunity. 2:1995;461-472.
22. Avdonin P. V., Cottet-Maire F., Afanasjeva G. V., Loktionova S. A., Lhote P., Ruegg U. T. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney. Int. 55:1999;2407-2414.
23. Kirk A. D., Jacobson L. M., Heisey D. M., Fass N. A., Sollinger H. W., Pirsch J. D. Post-transplant diastolic hypertension: Association with intragraft transforming growth factor-β, endothelin, and renin transcription. Transplantation. 64:1997;1716-1720.
24. 1 receptor subtype. Circ. Res. 73:1993;413-423.
25. Hayashida W., Kihara Y., Inagaki K., Iwanaga Y., Yasaka A., Sasayama S. Altered activation of c-Jun N-terminal kinase in the hypertrophied and failing rat left ventricular myocardium. J. Am. Coll. Cardiol. 33:1999;183A.
26. Hirsch A. T., Talsness C. E., Scunkert H., Paul M., Dzau V. J. Tissue-specific activation of cardiac angiotensin converting enzyme in heart failure. Circ. Res. 69:1991;475-482.